CD38 expression is an important prognostic marker in diffuse large B-cell lymphoma

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous hematologic malignancy with variable patient outcomes.
• Current prognostic markers for DLBCL are insufficient for precise treatment stratification.
• Cluster of differentiation (CD) 38 is implicated in cellular proliferation and disease progression.

Purpose of the Study:

• To investigate the clinical impact of CD38 expression on patient outcomes in de novo DLBCL.
• To determine if CD38 expression can serve as a predictive biomarker for DLBCL prognosis.

Main Methods:

• Flow cytometry was used to analyze surface CD38 expression in 137 de novo DLBCL patients.
• Patients were categorized into CD38-high and CD38-low groups based on survival analysis.
• Progression-free survival (PFS) and overall survival (OS) were evaluated using multivariate analysis.

Main Results:

• The 4-year PFS was significantly lower in the CD38-high group (31.6%) compared to the CD38-low group (60.7%).
• High CD38 expression was independently associated with significantly worse PFS (aHR=2.15) and OS (aHR=2.54).

Conclusions:

• High CD38 expression is an independent adverse prognostic factor in de novo DLBCL.
• CD38 expression levels can aid in predicting clinical outcomes for DLBCL patients.
• CD38 expression may guide the design of risk-adapted therapeutic strategies for DLBCL.